Ancora Advisors LLC Has $8.58 Million Stake in Enovis Co. (NYSE:ENOV)

Ancora Advisors LLC lessened its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 6.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 195,631 shares of the company's stock after selling 13,576 shares during the quarter. Ancora Advisors LLC owned about 0.34% of Enovis worth $8,584,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AXA S.A. grew its holdings in Enovis by 208.4% during the fourth quarter. AXA S.A. now owns 92,909 shares of the company's stock valued at $4,077,000 after purchasing an additional 62,784 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in Enovis during the fourth quarter worth about $1,388,000. Jane Street Group LLC grew its stake in Enovis by 110.2% in the fourth quarter. Jane Street Group LLC now owns 224,224 shares of the company's stock valued at $9,839,000 after acquiring an additional 117,540 shares during the period. Comerica Bank increased its holdings in shares of Enovis by 22.9% in the fourth quarter. Comerica Bank now owns 49,560 shares of the company's stock worth $2,175,000 after acquiring an additional 9,224 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Enovis by 15.8% during the 4th quarter. Northern Trust Corp now owns 547,686 shares of the company's stock valued at $24,032,000 after purchasing an additional 74,836 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Down 0.1 %

ENOV traded down $0.05 during trading hours on Tuesday, hitting $34.12. 780,867 shares of the company's stock were exchanged, compared to its average volume of 755,357. The stock's 50-day moving average is $35.54 and its two-hundred day moving average is $41.75. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis Co. has a 1-year low of $29.32 and a 1-year high of $53.84. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -15.58 and a beta of 1.79.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $560.98 million for the quarter, compared to analysts' expectations of $555.14 million. Sell-side analysts predict that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price target on shares of Enovis in a research note on Wednesday, April 9th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.